Brief
AGC Biologics adds Copenhagen to an unnamed customer’s Yokohama deal, now above EUR 0.5 billion
An unnamed global pharma company adds six commercial programs at AGC Biologics' Copenhagen site to five already placed in Yokohama. The release puts the total deal value above EUR 0.5 billion.
